CogNano
COGNANO is a drug discovery company that leverages unique VHH antibody data and advanced AI technology to develop highly accurate drug candidates and diagnostic agents. They efficiently identify therapeutic candidates based on extensive data, significantly accelerating drug discovery speed. The company addresses unmet medical needs, such as Triple-Negative Breast Cancer (TNBC), by identifying novel biomarkers. Their proprietary technology, IBMET, uses statistical methods and large language models (LLMs) to efficiently identify new antigens, leading to more precise drug development plans and higher success rates. COGNANO has a proprietary alpaca colony for generating VHH data and has accumulated over 300 million leads of antibody genes. They have published research on TNBC biomarkers and made their VHH dataset available for AI pre-training. The company's business model focuses on creating and providing comprehensive antigen-antibody pair information for drug discovery.
CogNano
COGNANO is a drug discovery company that leverages unique VHH antibody data and advanced AI technology to develop highly accurate drug candidates and diagnostic agents. They efficiently identify therapeutic candidates based on extensive data, significantly accelerating drug discovery speed. The company addresses unmet medical needs, such as Triple-Negative Breast Cancer (TNBC), by identifying novel biomarkers. Their proprietary technology, IBMET, uses statistical methods and large language models (LLMs) to efficiently identify new antigens, leading to more precise drug development plans and higher success rates. COGNANO has a proprietary alpaca colony for generating VHH data and has accumulated over 300 million leads of antibody genes. They have published research on TNBC biomarkers and made their VHH dataset available for AI pre-training. The company's business model focuses on creating and providing comprehensive antigen-antibody pair information for drug discovery.